Search Videos and More
News
Meet Baptist Health's 'Brains Behind the Brain'
Medical research is what has made today’s cures possible, and it is what is driving new life-saving therapies. At Baptist Health, a trio of physician-scientists focused on diseases of the brain – “the brains behind the brain” – continues to make vast contributions to scientific knowledge.
Video
Watch Now! Innovations in the Management of Pancreatic Cancer
Watch as our multidisciplinary panel of experts examine recently published trial data, novel systemic therapies, MR-guided radiation therapy, minimally invasive approaches to pancreatic surgery, irreversible electroporation (IRE) for pancreatic cancer, and more.
News
Liver Surgery: Minimally Invasive Techniques Can Be an Option
At the majority of cancer centers, patients with liver cancer who are candidates for a major liver resection surgery will be given no options other than traditional open surgery. The experts at Miami Cancer Institute, part of Baptist Health, however, will often perform a minimally invasive approach such as laparoscopic or robotic-assisted surgery when surgery for liver cancer is recommended.
News
Funding for Glioblastoma Research Key to Miami Cancer Institute's Growing Brain Cancer Program
Miami Cancer Institute researchers have received a $3.4 million R01 grant from the National Institutes of Health (NIH) and the National Cancer Institute (NCI) to further glioblastoma research. The award acknowledges the significant contributions of physician-investigators at Baptist Health Miami Cancer Institute.
News
Baptist Health is the Most Awarded Healthcare System in South Florida based on U.S. News & World Report 2024-2025 Rankings
Baptist Health has once again been recognized as one of the best healthcare providers in America and the most award-winning healthcare system in South Florida based on the 2024-2025 U.S. News & World Report rankings. The organization secured a total of 45 High Performing honors.
News
Miami Brain Symposium, Seventh Annual
The Miami Brain Symposium will focus on state-of-the-art approaches to the management of primary and metastatic central nervous systems tumors, along with an understanding of current standards of care and a look at future directions.
News
SRS with Immunotherapy Extends Survival in RCC with Brain Metastasis
According to Manmeet Ahluwalia, MD, MBA, FASCO, kidney cancer currently ranks as the fourth most common cancer to metastasize to the brain after lung cancer, breast cancer, and melanoma.
News
Minesh P. Mehta, MD, on NSCLC: Tumor Treating Fields for Brain Metastases
Minesh P. Mehta, MD, of Miami Cancer Institute, part of Baptist Health South Florida, discusses results from the METIS (EF-25) trial evaluating the efficacy and safety of tumor treating fields therapy following stereotactic radiosurgery in patients with mutation-negative non–small cell lung cancer (NSCLC) and brain metastases.
News
Miami Cancer Institute Leads First-in-World Brain Metastasis Trial
Baptist Health Miami Cancer Institute is leading a groundbreaking clinical trial that is studying the use of a new medication combined with stereotactic radiosurgery to combat metastatic brain cancer.
News
Miami Cancer Institute Publication Analyzes Role of Tissue-Agnostic Therapies for the Treatment of Primary Brain Tumors
Researchers from Miami Cancer Institute, part of Baptist Health South Florida, recently published a study in Trends in Cancer that analyzes the use of tissue-agnostic therapeutics in patients with primary brain tumors (PBTs). The publication describes the current and potential impact of tissue-agnostic therapies on the management of PBTs. As part of the publication, the researchers discuss data from clinical trials of tissue-agnostic targets for PBTs in the context of challenges in managing these tumors. They also describe additional tissue-agnostic targets that hold promise for benefiting patients with PBTs.
News
Advanced Prostate Cancer: Genetic Testing an Invaluable Tool
A study led by Baptist Health Miami Cancer Institute shows that patients with TP53, RB1 and PTEN mutated prostate cancer have a lower overall survival rate than patients who are biomarker negative. The results emphasize the importance of genetic testing for all advanced cancer patients, the researchers say.
News
Miami Cancer Institute to Host Fifth Global Summit on Immunotherapies for Hematologic Malignancies
Miami Cancer Institute, part of Baptist Health South Florida, announced it will host the Fifth Annual Global Summit on Immunotherapies for Hematologic Malignancies, to be held March 8-9, 2024, at the JW Marriott Hotel in Brickell, Miami, Fla.